logo-loader
viewAstraZeneca

AstraZeneca suffers clinical setback

Its drug targeting people with chronic obstructive pulmonary disease failed to make a statistically meaningful difference

screen saying "clinical trial"
Results from a second phase III study are expected later this quarter

AstraZeneca PLC (LON:AZN) has received another clinical setback. 

Top-line data of a phase III trial of its drug Fasenra for people with chronic obstructive pulmonary disease failed to show a statistically meaningful reduction of what it called 'exacerbations' in patients with the ailment.

Last month, the company announced mixed data from its study of its treatment Imfinzi used in harness with a currently-available medication, tremelimumab, for patients with lung cancer.

Mixed data from lung cancer drug 

It failed to improve the survival chances of sufferers taking it as a third-line treatment. This is a hard to treat group where the outlook is bleak, and analysts said there were no surprises there.

However, a sub-study that assessed Imfinzi on its own measured it against a group of PD-L1-positive patients receiving chemo showed it made “clinically meaningful” difference.

The big read-out for Imfinzi comes later this year when the results of from a further phase III trial are released. This consists of a group of PD-L1-positive patients taking the drug for the first time in combination with tremelimumab.

Returning to Fasenra, results from a second phase III study are expected later this quarter.

  

 

 

Quick facts: AstraZeneca

Price: 7217 GBX

LSE:AZN
Market: LSE
Market Cap: £94.68 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Things coming together nicely in Greenland, says Bluejay Mining's CEO

Rod McIllree, Bluejay Mining PLC’s (LON:JAY) chief executive, tells Proactive that all three of its projects in Greenland are shaping up nicely with plenty of interest from mining giants. Dundas is the flagship and here a bulk sample of mineral sands has been shipped to a Rio Tinto facility...

15 hours, 3 minutes ago

2 min read